108 related articles for article (PubMed ID: 26982980)
1. Prostate Stem Cell Antigen Expression in Radical Prostatectomy Specimens Predicts Early Biochemical Recurrence in Patients with High Risk Prostate Cancer Receiving Neoadjuvant Hormonal Therapy.
Kim SH; Park WS; Kim SH; Park B; Joo J; Lee GK; Joung JY; Seo HK; Chung J; Lee KH
PLoS One; 2016; 11(3):e0151646. PubMed ID: 26982980
[TBL] [Abstract][Full Text] [Related]
2. Biochemical Recurrence Prediction in High-Risk Prostate Cancer Patients, Following Robot-Assisted Radical Prostatectomy.
Yamaguchi N; Yumioka T; Iwamoto H; Masago T; Morizane S; Honda M; Sejima T; Takenaka A
Yonago Acta Med; 2016 Dec; 59(4):288-295. PubMed ID: 28070166
[TBL] [Abstract][Full Text] [Related]
3. Computer extracted gland features from H&E predicts prostate cancer recurrence comparably to a genomic companion diagnostic test: a large multi-site study.
Leo P; Janowczyk A; Elliott R; Janaki N; Bera K; Shiradkar R; Farré X; Fu P; El-Fahmawi A; Shahait M; Kim J; Lee D; Yamoah K; Rebbeck TR; Khani F; Robinson BD; Eklund L; Jambor I; Merisaari H; Ettala O; Taimen P; Aronen HJ; Boström PJ; Tewari A; Magi-Galluzzi C; Klein E; Purysko A; Nc Shih N; Feldman M; Gupta S; Lal P; Madabhushi A
NPJ Precis Oncol; 2021 May; 5(1):35. PubMed ID: 33941830
[TBL] [Abstract][Full Text] [Related]
4. Molecular profiling of radical prostatectomy tissue from patients with no sign of progression identifies
Yan W; Jamal M; Tan SH; Song Y; Young D; Chen Y; Katta S; Ying K; Ravindranath L; Woodle T; Kohaar I; Cullen J; Kagan J; Srivastava S; Dobi A; McLeod DG; Rosner IL; Sesterhenn IA; Srinivasan A; Srivastava S; Petrovics G
Oncotarget; 2019 Nov; 10(60):6466-6483. PubMed ID: 31741711
[TBL] [Abstract][Full Text] [Related]
5. Comparing outcomes between neoadjuvant hormonal therapy followed by prostatectomy versus upfront prostatectomy in high-risk prostate cancer: The road ahead.
Bhargava P
Indian J Urol; 2023; 39(2):173-174. PubMed ID: 37304992
[No Abstract] [Full Text] [Related]
6. PSCA, Cox-2, and Ki-67 are independent, predictive markers of biochemical recurrence in clinically localized prostate cancer: a retrospective study.
Kim SH; Park WS; Park BR; Joo J; Joung JY; Seo HK; Chung J; Lee KH
Asian J Androl; 2017; 19(4):458-462. PubMed ID: 27232854
[TBL] [Abstract][Full Text] [Related]
7. Favorable vs Unfavorable Intermediate-Risk Prostate Cancer: A Review of the New Classification System and Its Impact on Treatment Recommendations.
Serrano NA; Anscher MS
Oncology (Williston Park); 2016 Mar; 30(3):229-36. PubMed ID: 26984216
[TBL] [Abstract][Full Text] [Related]
8. The implications of ageing and life expectancy in prostate cancer treatment.
Kalra S; Basourakos S; Abouassi A; Achim M; Volk RJ; Hoffman KE; Davis JW; Kim J
Nat Rev Urol; 2016 May; 13(5):289-95. PubMed ID: 27001016
[TBL] [Abstract][Full Text] [Related]
9. The importance of surgical margins in prostate cancer.
Sooriakumaran P; Dev HS; Skarecky D; Ahlering T
J Surg Oncol; 2016 Mar; 113(3):310-5. PubMed ID: 27004601
[TBL] [Abstract][Full Text] [Related]
10. Multifaceted and personalized therapy of advanced prostate cancer.
Thakur MK; Vaishampayan U
Curr Opin Oncol; 2016 May; 28(3):222-31. PubMed ID: 26992199
[TBL] [Abstract][Full Text] [Related]
11. Pre-diagnostic circulating sex hormone levels and risk of prostate cancer by ERG tumour protein expression.
Graff RE; Meisner A; Ahearn TU; Fiorentino M; Loda M; Giovannucci EL; Mucci LA; Pettersson A
Br J Cancer; 2016 Apr; 114(8):939-44. PubMed ID: 26986253
[TBL] [Abstract][Full Text] [Related]
12. Androgen receptor splice variant 7 (AR-V7) and drug efficacy in castration-resistant prostate cancer: Biomarker for treatment selection exclusion or inclusion?
Leibrand CR; Price DK; Figg WD
Cancer Biol Ther; 2016 May; 17(5):467-9. PubMed ID: 26985596
[TBL] [Abstract][Full Text] [Related]
13. An Epigenetic Reprogramming Strategy to Resensitize Radioresistant Prostate Cancer Cells.
Peitzsch C; Cojoc M; Hein L; Kurth I; Mäbert K; Trautmann F; Klink B; Schröck E; Wirth MP; Krause M; Stakhovsky EA; Telegeev GD; Novotny V; Toma M; Muders M; Baretton GB; Frame FM; Maitland NJ; Baumann M; Dubrovska A
Cancer Res; 2016 May; 76(9):2637-51. PubMed ID: 26984757
[TBL] [Abstract][Full Text] [Related]
14. Portfolio of prospective clinical trials including brachytherapy: an analysis of the ClinicalTrials.gov database.
Cihoric N; Tsikkinis A; Miguelez CG; Strnad V; Soldatovic I; Ghadjar P; Jeremic B; Dal Pra A; Aebersold DM; Lössl K
Radiat Oncol; 2016 Mar; 11():48. PubMed ID: 27005770
[TBL] [Abstract][Full Text] [Related]
15. Chemotherapy following radium-223 dichloride treatment in ALSYMPCA.
Sartor O; Hoskin P; Coleman RE; Nilsson S; Vogelzang NJ; Petrenciuc O; Staudacher K; Thuresson M; Parker C
Prostate; 2016 Jul; 76(10):905-16. PubMed ID: 27004570
[TBL] [Abstract][Full Text] [Related]
16. Abiraterone acetate in metastatic castration-resistant prostate cancer - the unanticipated real-world clinical experience.
Poon DM; Chan K; Lee SH; Chan TW; Sze H; Lee EK; Lam D; Chan MF
BMC Urol; 2016 Mar; 16():12. PubMed ID: 27001043
[TBL] [Abstract][Full Text] [Related]
17. Clinical Utility of Biomarkers in Localized Prostate Cancer.
Leapman MS; Nguyen HG; Cooperberg MR
Curr Oncol Rep; 2016 May; 18(5):30. PubMed ID: 27023445
[TBL] [Abstract][Full Text] [Related]
18. Non‑invasive prostate cancer detection by measuring miRNA variants (isomiRs) in urine extracellular vesicles.
Koppers-Lalic D; Hackenberg M; de Menezes R; Misovic B; Wachalska M; Geldof A; Zini N; de Reijke T; Wurdinger T; Vis A; van Moorselaar J; Pegtel M; Bijnsdorp I
Oncotarget; 2016 Apr; 7(16):22566-78. PubMed ID: 26992225
[TBL] [Abstract][Full Text] [Related]
19. An Examination of the Association between FOXA1 Staining Level and Biochemical Recurrence following Salvage Radiation Therapy for Recurrent Prostate Cancer.
Heckman MG; Robinson JL; Tzou KS; Parker AS; Wu KJ; Hilton TW; Howat WJ; Miller JL; Kreinest PA; Pisansky TM; Schild SE; Peterson JL; Vallow LA; Carroll JS; Buskirk SJ
PLoS One; 2016; 11(3):e0151785. PubMed ID: 26986977
[TBL] [Abstract][Full Text] [Related]
20. Relationship between CYP17 gene polymorphisms and risk of prostate cancer.
Song J; Tao ZH; Liu XY; Gong S; Gan L
Genet Mol Res; 2016 Feb; 15(1):15017866. PubMed ID: 26985923
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
